Month: November 2022

On August 31, 2002, Goker, Hakan; Kus, Canan; Boykin, David W.; Yildiz, Sulhiye; Altanlar, Nurten published an article.Formula: C7H3ClN2O2 The title of the article was Synthesis of some new 2-substituted-phenyl-1H-benzimidazole-5-carbonitriles and their potent activity against Candida species. And the article contained the following:

New 2-substituted-phenyl-1H-benzimidazole-5-carboxylic acids, ethyl-5-carboxylate, -5-carboxamides,-5-carboxaldehyde, -5-chloro-, -5-trifluoromethyl, and -5-carbonitriles, -6-carbonitrile were prepared and evaluated in vitro against Candida species. The cyano substituted compounds exhibited the greatest activity with MIC values of 3.12 μg/mL, values similar to that of fluconazole. The experimental process involved the reaction of 3-Chloro-4-nitrobenzonitrile(cas: 34662-29-8).Formula: C7H3ClN2O2

The Article related to substituted phenyl benzimidazole carbonitrile candida activity, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Formula: C7H3ClN2O2

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On April 13, 2006, Ng, Raymond; Sui, Zhihua; Guan, Jihua; Lanter, James C.; Alford, Vernon C., Jr. published a patent.COA of Formula: C8H6F3N3 The title of the patent was Preparation of benzimidazole derivatives as selective androgen receptor modulators. And the patent contained the following:

Title compounds represented by the formula I [wherein R1 = H, alkyl, CH2-aryl, alkyl-OH, etc.; R2 = H, halo, (halo)alkyl, etc.; n = 0 or 1; R10 = H, halo, (halo)alkyl or OCOR8; R8 = (cyclo)alkyl, (hetero)aryl, aralkyl, etc.; R11 = H or halo; or R10and R11 are taken together with the carbon atom to which they are bound to form CO, C=N(OH) or C=N(O-alkyl); R12 = (halo)alkyl, alkyl-OH, CH2-aryl, etc.; and pharmaceutically acceptable salts thereof] were prepared as selective androgen receptor modulators (SARMS). For example, oxidation of 2-(5,6-dichloro-1-ethyl-1H-benzimidazol-2-yl)-1-ethanesulfanylpropan-2-ol by mCPBA gave II. II showed activity in ventral prostate and seminal vesicle weight in vivo assay and ventral prostate and levator ani weight in vivo assay. Thus, I and their pharmaceutical compositions are useful for the treatment of disorders and conditions modulated by the androgen receptor. The experimental process involved the reaction of 4,5-Diamino-2-(trifluoromethyl)benzonitrile(cas: 882978-62-3).COA of Formula: C8H6F3N3

The Article related to benzimidazole preparation selective androgen receptor modulator, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.COA of Formula: C8H6F3N3

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On April 13, 2006, Ng, Raymond; Sui, Zhihua; Guan, Jihua; Lanter, James C.; Alford, Vernon C., Jr. published a patent.Electric Literature of 882978-62-3 The title of the patent was Preparation of benzimidazole derivatives as selective androgen receptor modulators. And the patent contained the following:

Title compounds represented by the formula I [wherein R1 = H, alkyl, CH2-aryl, alkyl-OH, etc.; R2, R3 = independently H, halo, (halo)alkyl, etc.; n = 0 or 1; R4 = H, (halo)alkyl or OCOR8; R8 = (cyclo)alkyl, (hetero)aryl, aralkyl, etc.; R5 = H, halo or (halo)alkyl; R6 = (halo)alkyl, alkyl-OH, CH2-aryl, etc.; and pharmaceutically acceptable salts thereof] were prepared as selective androgen receptor modulators (SARMS). For example, oxidation of 2-(5,6-dichloro-1-ethyl-1H-benzimidazol-2-yl)-1-ethanesulfanylpropan-2-ol by mCPBA gave II. II showed activity in ventral prostate and seminal vesicle weight in vivo assay and ventral prostate and levator ani weight in vivo assay. Thus, I and their pharmaceutical compositions are useful for the treatment of disorders and conditions modulated by the androgen receptor. The experimental process involved the reaction of 4,5-Diamino-2-(trifluoromethyl)benzonitrile(cas: 882978-62-3).Electric Literature of 882978-62-3

The Article related to benzimidazole preparation selective androgen receptor modulator, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Electric Literature of 882978-62-3

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On May 3, 2018, Harried, Scott S.; Resnick, Lynn; Topalov, George T.; Boyd, Steven A.; Belardi, Justin K.; Flentge, Charles A.; Hale, James S.; Mareska, David A.; Zhang, Kai published a patent.Name: 3-Chloro-4-nitrobenzonitrile The title of the patent was Preparation of benzoimidazolylamide derivatives for use as Kv7 potassium channel activators. And the patent contained the following:

Title compounds I [A = alkyl; X = H, F, alkyl, or (un)substituted Ph; Y = H, F, or a moiety having a mol. weight of 15 Da to 300 Da and consisting of 2-5 chem. elements, wherein the chem. elements are independently C, H, O, or F; Z = (un)substituted cyclobutyl, Ph, iso-Pr, or t-butyl; R1 = CN, OMe, CF3, etc.; R2, R3, and R4 independently = H, F, Cl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as Kv7 potassium channel activators. Thus, e.g., II was prepared by a multistep procedure (preparation given). Select I were evaluated in Kv7.2/7.3 activation assays (data given). The experimental process involved the reaction of 3-Chloro-4-nitrobenzonitrile(cas: 34662-29-8).Name: 3-Chloro-4-nitrobenzonitrile

The Article related to benzoimidazolylamide preparation kv7 potassium channel activator, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Name: 3-Chloro-4-nitrobenzonitrile

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On May 12, 2011, Hallman, Jason; Laudeman, Christopher; Liu, Ronggang; Miller, Aaron; Moore, Michael Lee; Dock, Steven; Musso, David; Parrish, Cynthia published a patent.Formula: C7H3ClN2O2 The title of the patent was Benzimidazoles as fatty acid synthase inhibitors and their preparation and use for the treatment of cancer. And the patent contained the following:

The invention relates to benzimidazole derivatives of formula I, which are fatty acid synthase inhibitors and which are useful in the treatment of cancer. Compounds of formula I wherein each R1 is independently halo, C1-6 alkyl, alkoxy, CN, etc.; R2 is (un)substituted aryl and (un)substituted heteroaryl; R3 is amino, alkylamino, dialkylamino, etc.; each R4 is C1-6 alkyl, alkoxy, OH and halo; each Y is independently C and N; n is 0 to 4; m is 0 to 4; provided that at least two Y are C; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their fatty acid synthase inhibitory activity. From the assay, it was determined that compound II exhibited a pIC50 value of 7.26. The experimental process involved the reaction of 3-Chloro-4-nitrobenzonitrile(cas: 34662-29-8).Formula: C7H3ClN2O2

The Article related to benzimidazole preparation fatty acid synthase inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Formula: C7H3ClN2O2

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On January 31, 2008, Efremov, Ivan Viktorovich; Rogers, Bruce Nelsen; Duplantier, Allen Jacob; Zhang, Lei; Zhang, Qian; Maklad, Noha Serour; Evrard, Edelweiss Virginie; Brodney, Michael A. published a patent.Formula: C7H3ClN2O2 The title of the patent was Benzimidazolyl compounds as potentiators of mGluR2 subtype of glutamate receptor and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. Compounds of formula I wherein X1 is CR7; X2 is CR4; X3 is CR6; X4 is (CHR9)0-2; X5 is CH2, CH2CH2; X8 is CR3; R1, R2, R3, R4 and R6 are independently H, halo, CN, OH and derivatives, alkyl, alkenyl, etc.; R7 is H, halo, OH, alkyl, alkoxy, CN and alkyl-CO; R5, R8 and R9 are independently halo, CN, OH and derivatives, CO2H and derivatives, NH2 and derivatives, H, alkyl, alkenyl, etc.; R11, R12, R13 and R14 are independently halo, CN, H, CO2H and derivatives, CONH2 and derivatives, OH and derivatives, NH2 and derivatives, alkyl, etc.; R17 is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted cycloalkyl, and (un)substituted cycloalkenyl; R18 is H, halo and alkyl; R19 are H; R8R19 taken together to form =O; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II•HCl was prepared by reductive alkylation of 4-(2-methoxy-4-trifluoromethylphenyl)piperidine hydrochloride with 1-methyl-1H-benzo[d]imidazole-2-carboxaldehyde. All the invention compounds were evaluated for their ability to potentiate mGluR2. From the assay, it was determined that compound II exhibited EC50 value of < 0.0193 μM. The experimental process involved the reaction of 3-Chloro-4-nitrobenzonitrile(cas: 34662-29-8).Formula: C7H3ClN2O2

The Article related to benzimidazolyl compound preparation potentiator mglur2 treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Formula: C7H3ClN2O2

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On February 1, 2007, Ng, Raymond A.; Guan, Jihua; Alford, Vernon C.; Lanter, James C.; Allan, George F.; Sbriscia, Tifanie; Linton, Olivia; Lundeen, Scott G.; Sui, Zhihua published an article.Recommanded Product: 4,5-Diamino-2-(trifluoromethyl)benzonitrile The title of the article was Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-Dichloro-benzimidazole derivatives. And the article contained the following:

The synthesis and in vivo SAR of 5,6-dichloro-benzimidazole derivatives as novel selective androgen receptor antagonists were described. During screening of 2-alkyl benzimidazoles, it was found that a trifluoromethyl group greatly enhances antagonist activity in the prostate. Benzimidazole I was a potent AR antagonist in the rat prostate (ID50 = 0.15 mg/day). The experimental process involved the reaction of 4,5-Diamino-2-(trifluoromethyl)benzonitrile(cas: 882978-62-3).Recommanded Product: 4,5-Diamino-2-(trifluoromethyl)benzonitrile

The Article related to benzimidazole dichloro derivative preparation androgen receptor antagonist sar, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Recommanded Product: 4,5-Diamino-2-(trifluoromethyl)benzonitrile

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On November 9, 2017, Larson, Peter; Kucaba, Tamara A.; Xiong, Zhengming; Olin, Michael; Griffith, Thomas S.; Ferguson, David M. published an article.Application of 5098-14-6 The title of the article was Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8. And the article contained the following:

A series of N1-modified imidazoquinolines were synthesized and screened for Toll-like receptors (TLR) 7 and 8 activities to identify recognition elements that confer high affinity binding and selectivity. These receptors are key targets in the development of immunomodulatory agents that signal the NF-κB mediated transcription of pro-inflammatory chemokines and cytokines. Results are presented showing both TLR7/8 activations are highly correlated to N1-substitution, with TLR8 selectivity achieved through inclusion of an ethyl-, propyl-, or butylamino group at this position. While the structure-activity relationship anal. indicates TLR7 activity is less sensitive to N1-modification, extension of the aminoalkyl chain length to pentyl and p-methylbenzyl elicited high affinity TLR7 binding. Cytokine profiles are also reported that show the pure TLR8 agonist [4-amino-2-butyl-1-(2-aminoethyl)-7-methoxycarbonyl-1H-imidazo[4,5-c]quinoline] (I) induces higher levels of IL-1β, IL-12, and IFNγ when compared with TLR7 selective or mixed TLR7/8 agonists. The results are consistent with previous work suggesting TLR8 agonists are Th1 polarizing and may help promote cell-mediated immunity. The experimental process involved the reaction of 2-Aminomalononitrile 4-methylbenzenesulfonate(cas: 5098-14-6).Application of 5098-14-6

The Article related to imidazoquinoline preparation tlr7 tlr8 agonist structure activity relationship, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Application of 5098-14-6

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On August 31, 1990, Frank, I.; Zeller, M. published an article.Formula: C10H11N3O3S The title of the article was 5-Amino-4-cyano-1-(hetero)arylimidazoles. And the article contained the following:

Title compounds I (R = 2-pyridyl, 3-pyridyl, 2-pyrimidinyl, 2-ClC6H4, 4-ClC6H4, 2,4-Cl2C6H3, 2,4-Me2C6H3, 5-chloro-2-pyridyl, 3,5-dichloro-2-pyridyl, 2-chloro-3-pyridyl) were prepared by the cyclocondensation of RN:CHOEt with NCCH(NH2)CN.p-MeC6H4SO3H. The experimental process involved the reaction of 2-Aminomalononitrile 4-methylbenzenesulfonate(cas: 5098-14-6).Formula: C10H11N3O3S

The Article related to aminocyanoheteroarylimidazole, imidazole aminocyanoheteroaryl, formimidate aminomalodinitrile cyclocondensation, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Formula: C10H11N3O3S

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On October 23, 2003, Shimojo, Masato; Taniguchi, Kana published a patent.Related Products of 34662-29-8 The title of the patent was Preparation of imidazoarenes as prostaglandin E2 subtype EP4 receptor antagonists for treatment of IL-6 involved diseases. And the patent contained the following:

The present invention relates to the use of a prostaglandin E2 (PGE2) subtype EP4 receptor ligand in the manufacture of a medicament for the treatment of interleukin 6 (IL-6) involved diseases, such as alc. cirrhosis, amyloidosis, atherosclerosis, cardiac disease, sclerosis, and organ transplantation reactions (no data). The invention also relates to the assay which comprises culturing peripheral whole blood with a test compound and determining the effect of the compound on PGE2-induced whole blood cells activation. Three hundred eighty title compounds I [wherein Y1-Y4 = N, CH, CL; R1 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, pyrrolidinyl, amino, etc.; A = (un)substituted 5-6 membered (un)substituted monocyclic (hetero)aromatic ring; B = halo-substituted alkylene, cycloalkylene, alkenylene, alkynylene, alkyleneoxy, etc., optionally substituted with an oxo or alkyl group; W = amino, O, S, bond, etc.; R2 = H, OH, alkyl, alkoxy; Z = 5-12 membered (un)substituted monocyclic or bicyclic (hetero)aryl; L = halo, alkyl, haloalkyl, OH, alkoxy, haloalkoxy, alkylthio, NO2, amino, etc.] were prepared Thus, cycloaddition of 2-[4-[(3-amino-4,6-dimethyl-2-pyridinyl)amino]phenyl]ethanol (4-step preparation given) with propionyl chloride in toluene provided 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl]ethyl propionate, which was treated with aqueous LiOH to give the ethanol derivative (86%). Chlorination (90%) using thionyl chloride, conversion to the azide (85%), and Pd/C catalyzed hydrogenation afforded the amine (94%). Coupling of the amine with p-toluenesulfonyl isocyanate in CH2Cl2 gave II (56%). The latter significantly inhibited IL-6 secretion by PGE2 in ConA-stimulated human peripheral blood mononuclear cells (PBMC). The experimental process involved the reaction of 3-Chloro-4-nitrobenzonitrile(cas: 34662-29-8).Related Products of 34662-29-8

The Article related to imidazoarene preparation composition prostaglandin e2 ep4 antagonist, benzimidazole imidazopyridine preparation composition il6 disease, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Related Products of 34662-29-8

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts